Melanoma: all 3,073 studies

Page 19 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and MetabolomicsStatus unknownNCT03643289
• Trial of Surgical Excision Margins in Thick Primary Melanoma - 2CompletedNCT03638492Not applicable
• TIL and Anti-PD1 in Metastatic MelanomaActive, not recruitingNCT03638375Phase 1/2
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineCompletedNCT03633110Phase 1/2
• Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma PatientsCompletedNCT03627026Not applicable
• Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCompletedNCT03617328Phase 1/2
• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2
• Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny DestinationsCompletedNCT03607578Not applicable
• Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in SpainActive, not recruitingNCT03605771
• Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2
• A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedNCT03597282Phase 1
• Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401No longer availableNCT03593499
• Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedNCT03590054Phase 1
• A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT03565406Phase 1
• TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)CompletedNCT03555032Phase 1/2
• Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEKCompletedNCT03553329
• QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.CompletedNCT03552718Phase 1
• Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously StudyCompletedNCT03545334Not applicable
• Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1
• Evaluation of Oncoxin-Viusid® in Cutaneous MelanomaCompletedNCT03541148Phase 2
• UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic MelanomaCompletedNCT03538314Phase 1
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
• Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)CompletedNCT03535077
• Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)Active, not recruitingNCT03534635Phase 2
• Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2
• A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1
• PD-L1 PET Imaging in Melanoma PatientsCompletedNCT03520634Not applicable
• Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)CompletedNCT03518814
• Pilot Study of Intervention to Reduce Sunburns in Melanoma SurvivorsWithdrawnNCT03518229Not applicable
• A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedNCT03517488Phase 1
• To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.Status unknownNCT03514901Phase 2
• Reflectance Confocal Microscopy to Diagnose MM & LMCompletedNCT03508297
• Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced MelanomaCompletedNCT03504696
• CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)CompletedNCT03504488Phase 1/2
• Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaCompletedNCT03501368Phase 1
• Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients with Metastatic Malignant Melanoma Treated with Targeted Therapies or Immunotherapy ( MALT )CompletedNCT03493230Not applicable
• TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)CompletedNCT03475134Phase 1
• Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic MelanomaCompletedNCT03472027Phase 1
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal MelanomaActive, not recruitingNCT03467516Phase 2
• Melanoma Accuracy Study; Phase 2TerminatedNCT03464604
• Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene AberrationsStatus unknownNCT03454919Phase 2
• Impact of Dietary Intervention on Tumor Immunity: the DigesT TrialStatus unknownNCT03454282Not applicable
• Long Term Quality of Life in Melanoma Patients in NetherlandsCompletedNCT03450876
• Validation of Ferromagnetic Tracer in Melanoma Sentinel NodeStatus unknownNCT03449615
• ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral MetastasesWithdrawnNCT03448666Phase 2
• Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United KingdomCompletedNCT03448497
• Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination TherapyCompletedNCT03438279
• HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal MelanomaStatus unknownNCT03435302Phase 3
• Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain MetastasesTerminatedNCT03430947Phase 2
• A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic MelanomaCompletedNCT03430297Phase 3
• Preventing Lymphedema in Axillary Lymph Node DissectionTerminatedNCT03428581Not applicable
• Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1
• A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced MelanomaStatus unknownNCT03422445Phase 2
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
• Treating Patients With Melanoma and ALK Alterations With EnsartinibActive, not recruitingNCT03420508Phase 2
• Therapeutic Drug Monitoring of BRAF-mutated Advanced MelanomaCompletedNCT03416933Not applicable
• Identifying the Predictive Factors of Response to PD-1 or PD-L1 AntagonistsTerminatedNCT03412058Not applicable
• PET Imaging of the Immune System Using Analog ProbesCompletedNCT03409419
• CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)CompletedNCT03408587Phase 1
• Safety of Intranodal ECI-006 in Melanoma PatientsTerminatedNCT03394937Phase 1
• A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaTerminatedNCT03391050Phase 1/2
• Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint InhibitorsStatus unknownNCT03385486Phase 1
• Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by SurgerySuspendedNCT03384836Phase 1/2
• Clinical Study of Apatinib as the Second-line Therapy in Malignant MelanomaStatus unknownNCT03383237Phase 2
• The Impact of Melanoma and Drug Treatment in the Real WorldCompletedNCT03379454
• Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma PatientsStatus unknownNCT03374839Phase 1/2
• Artificial Intelligence-assisted Evaluation of Pigmented Skin LesionsStatus unknownNCT03362138
• Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic MelanomaCompletedNCT03356470
• Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)TerminatedNCT03354962Phase 1/2
• Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed ImmunotherapyStatus unknownNCT03353402Phase 1
• Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic MelanomaCompletedNCT03352947Phase 2
• TNF in Melanoma Patients Treated With ImmunotherapyCompletedNCT03348891Not applicable
• Suicide Plus Immune Gene Therapy for Advanced MelanomaTerminatedNCT03338777Early Phase 1
• Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or MelanomaCompletedNCT03336606Phase 1
• Optimization of the Patient Care Pathway in Immuno-oncologyCompletedNCT03329755Not applicable
• Achieving Self-directed Integrated Cancer Aftercare (ASICA) in MelanomaCompletedNCT03328247Not applicable
• Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint InhibitorsCompletedNCT03326973
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Post-ATU Study of NivolumabCompletedNCT03325257
• Molecular Characterization of Primary Mucosal MelanomaCompletedNCT03319693
• Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1Status unknownNCT03313544Phase 4
• Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic MelanomaStatus unknownNCT03313323Phase 2
• Expanded Access for Pembrolizumab (MK-3475)No longer availableNCT03311542
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced MelanomaActive, not recruitingNCT03311308Phase 1
• Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaWithdrawnNCT03297463Phase 1/2
• A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
• TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanomaCompletedNCT03293784Phase 1
• Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACCStatus unknownNCT03291002Phase 1
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
• The French E3N Prospective Cohort StudyActive, not recruitingNCT03285230
• REO13 Melanoma With of Without GM-CSFWithdrawnNCT03282188Phase 1/2
• 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 TherapyCompletedNCT03278665Phase 1/2
• International Trial of the Efficacy and Safety of BCD-100 in Patients With MelanomaStatus unknownNCT03269565Phase 2
• Nevus Doctor Clinical Decision Support for GPsCompletedNCT03246412Not applicable
• Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStatus unknownNCT03241186Phase 2
• Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibActive, not recruitingNCT03235245Phase 2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic MelanomaCompletedNCT03225365Not applicable
• Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma PatientsTerminatedNCT03224208Phase 2
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2

← Melanoma overview